Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?

BACKGROUND: Previous work suggests that Japanese patients with type 2 diabetes mellitus (T2DM) may respond more favorably to a DPP-4 (dipeptidyl peptidase-4) inhibitor than Caucasians. We aimed to compare the efficacy of the DPP-4 inhibitor vildagliptin (50 mg twice daily [bid]) between Japanese and...

Descripción completa

Detalles Bibliográficos
Autores principales: Foley, James E, Bhosekar, Vaishali, Kawamori, Ryuzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725625/
https://www.ncbi.nlm.nih.gov/pubmed/26855580
http://dx.doi.org/10.2147/VHRM.S96971

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725625/
https://www.ncbi.nlm.nih.gov/pubmed/26855580
http://dx.doi.org/10.2147/VHRM.S96971

Ejemplares similares